Advances In The Mechanism And New Therapies Of Alopecia Areata

Alopecia areata (AA) is a T-cell mediated hair loss condition with an immunoinflammatory basis, affecting about 2% of the global population. Current treatments are limited and often ineffective, especially for severe cases. Recent advances have identified Janus kinase (JAK) inhibitors as promising therapies. Baricitinib, a JAK1/2 inhibitor, is the only FDA-approved treatment for severe AA in adults. A phase 2b–3 trial showed that ritlecitinib, a JAK3/TEC kinase inhibitor, is effective and well-tolerated in patients aged 12 and older. Other JAK inhibitors like deuruxolitinib and ruxolitinib also show potential. The study highlights the need for continued research into targeted therapies to address the significant unmet needs in AA treatment, particularly for adolescents and those with severe disease.